In this study, we observed that among patients with AML 65 years old or older, who comprise the majority of all patients with AML, the prognostic impact of favorable karyotype, FLT3 mutations and NPM1 mutations on OS is not statistically significant. This evidence concerns the gene FLT3 and acute myeloid leukemia.